Novartis AG ADR Earnings

The next earnings date for Novartis AG ADR is October 28, 2025.

They are scheduled to announce earnings before the market opens that day.

Analyst Estimates of Novartis AG ADR Earnings

Report DateEstimated Earnings Per Share
10/28/2025$2.29

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Novartis AG ADR Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
07/17/2025Before Market$2.422.11%
04/29/2025Before Market$2.284.95%
01/31/2025Before Market$1.9811.44%
10/29/2024Before Market$2.065.10%
07/18/2024Before Market$1.974.23%
04/23/2024Before Market$1.806.51%
01/31/2024Before Market$1.53-9.47%
10/24/2023Before Market$1.837.65%
07/19/2023Before Market$1.838.93%
04/25/2023Before Market$1.7110.32%
02/01/2023Before Market$1.525.56%
10/25/2022Before Market$1.581.94%
07/19/2022Before Market$1.564.00%
04/26/2022Before Market$1.461.39%
02/02/2022Before Market$1.40-0.71%
10/26/2021Before Market$1.713.64%
07/21/2021After Market$1.668.50%
04/27/2021Before Market$1.52-4.40%
01/26/2021Before Market$1.34-1.47%
10/27/2020Before Market$1.524.83%
07/21/2020Before Market$1.363.82%
04/28/2020After Market$1.5613.87%
01/29/2020After Market$1.322.33%
10/22/2019After Market$1.413.68%
07/18/2019Before Market$1.349.84%
04/24/2019Before Market$1.214.31%
01/30/2019Before Market$1.25-2.34%
10/18/2018Before Market$1.321.54%
07/18/2018Before Market$1.291.57%
04/19/2018Before Market$1.280.00%
01/24/2018Before Market$1.211.68%
10/24/2017Before Market$1.293.20%
07/18/2017Before Market$1.211.68%
04/25/2017Before Market$1.131.80%
01/25/2017Before Market$1.110.00%
10/25/2016Before Market$1.233.36%
07/19/2016Before Market$1.234.24%
04/21/2016Before Market$1.16-1.69%
01/27/2016Before Market$1.09-7.63%
10/27/2015Before Market$1.27-3.05%
07/21/2015Before Market$1.250.81%
04/23/2015Before Market$1.2917.27%
01/27/2015Before Market$1.210.00%
10/28/2014Before Market$1.376.20%
07/17/2014---$1.34-4.29%
04/24/2014---$1.28-3.76%
01/29/2014---$1.19-5.56%
10/22/2013---$1.25-4.58%
07/17/2013---$1.300.78%
04/24/2013---$1.323.13%
01/23/2013---$1.276.72%
10/25/2012---$1.34-1.47%
07/19/2012---$1.386.98%
04/24/2012---$1.27-3.79%
01/25/2012---$1.232.50%
10/25/2011---$1.45-3.97%
07/19/2011---$1.485.71%
04/19/2011---$1.417.63%
01/27/2011---$1.14-8.80%
10/21/2010---$1.275.83%
07/15/2010---$1.206.19%
04/20/2010---$1.4417.07%
01/26/2010---$1.01-8.18%
10/22/2009---$0.92-3.16%
07/16/2009---$0.894.71%
04/23/2009---$0.870.00%
01/28/2009---$0.66-16.46%
10/20/2008---$0.92-3.16%
07/17/2008---$0.985.38%
04/21/2008---$1.0214.61%
01/17/2008---$0.40-45.21%
10/18/2007---$0.68-10.53%
07/17/2007---$0.836.41%
04/23/2007---$0.929.52%
01/18/2007---$0.70-10.26%
10/19/2006---$0.793.95%
07/17/2006---$0.73-7.59%
04/24/2006---$0.8316.90%
01/19/2006---$0.58-18.31%
10/18/2005---$0.71-1.39%
07/14/2005---$0.706.06%
04/21/2005---$0.63---
01/20/2005---$0.56-6.67%
10/21/2004---$0.638.62%
07/20/2004---$0.636.78%
04/22/2004---$0.52-1.89%
01/22/2004---$0.553.77%
10/20/2003---$0.520.00%
07/21/2003---$0.521.96%
04/15/2003---$0.43-6.52%
01/23/2003---$0.457.14%
10/17/2002---$0.477.11%
06/30/2002---$0.49---
03/31/2002---$0.41---
03/17/1998---$0.51-8.93%
09/02/1997---$0.790.00%
04/22/1997---$0.5215.56%

More About Novartis AG ADR

Website
https://www.novartis.com
Country
USA
Full Time Employees
75,883

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

“Novartis AG ADR Earnings” Can Refer to the Novartis AG ADR Earnings Date

Some people say “Novartis AG ADR earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Novartis AG ADR position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Novartis AG ADR Stock on the Earnings Date

If you own Novartis AG ADR stock (NVS) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Novartis AG ADR might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Novartis AG ADR shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Novartis AG ADR Earnings

You can contact us any time if you would like to ask questions about Novartis AG ADR earnings or anything else related to the stock market.